Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Perspective Article

An Overview on COVID-19: Clinical Features, Treatment and Prevention

Author(s): Shahid Ud Din Wani*, Surya Prakash Gautam and Zulfkar Latief Qadrie

Volume 2 , Issue 3 , 2021

Published on: 18 August, 2020

Page: [291 - 295] Pages: 5

DOI: 10.2174/2666796701999200818145609

Abstract

Background: The Coronavirus disease 2019 (COVID-19) is a transmissible illness produced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has now quickly expanded since its outbreak in Wuhan City of Hubei region of China to the other parts of the world. In accordance with the Centers for Disease Control and Prevention (CDC), the spread of COVID-19 emerges typically human- to-humans through respiratory droplets within an area of 1-2 meters.

Aims and Objective: In the present perspective, we have discussed some of the measures taken to prevent and treat the patients suffering from COVID-19, and how to restrict further spread of COVID-19 due to SARS-CoV-2.

Results: The general clinical properties are fever, cough, sore throat, headache, tiredness, myalgia and difficulty in breathing. Presently no approved treatments for COVID-19, as of now, no pharmaceutical products have been revealed to be harmless and efficient for the management of COVID-19. Various anti-viral medicines e.g. ribavirin, lopinavir, and ritonavir have been utilized supported on the familiarity with SARS and MERS. Many drugs and vaccines are currently being studied in clinical trials, jointly (Solidarity trial) co-sponsored by the WHO.

Conclusion: The use of a mask by fit people in community areas to guard against respiratory viral disease is presently recommended by WHO. Patients must be kept in individual rooms, the rooms, surfaces and equipment should go through standard sanitization, possibly with sodium hypochlorite. Consequently, apart from restricting this epidemic, efforts should be made to plan wide-ranging procedures to thwart potential outbreaks of the zoonotic sources.

Keywords: Coronaviruses, infection control, clinical features, treatment, prevention measures, COVID-19.

[1]
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern Lancet 2020 395(10223): 470-3.
[http://dx.doi.org/10.1016/S0140-6736(20)30185-9] [PMID: 31986257 ]
[2]
Worldometer. Coronavirus Outbreak. Available from: https://www.worldometers.info/coronavirus/
[3]
Pene F, Merlat A, Vabret A, et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 2003; 37(7): 929-32.
[http://dx.doi.org/10.1086/377612] [PMID: 13130404]
[4]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507- 13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[5]
Weiss SR, Leibowitz JL. Coronavirus pathogenesis Adv Virus Res 2011; 81: 85-164
[http://dx.doi.org/10.1016/B978-0-12-385885-6.00009-2] [PMID: 22094080]
[6]
Tok TT, Tatar G. Structures and functions of coronavirus proteins: molecular modeling of viral nucleoprotein. Int J Virol Infect Dis 2017; 2(1): 1-7.
[7]
Centers for Disease Control and Prevention. How COVID-19 spreads Available from: https://www.cdc.gov/coronavirus/2019ncov/about/transmission.html
[8]
Centers for Disease Control and Prevention. Persons evaluated for 2019 novel coronavirus—United States. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6906e1.htm
[9]
World Health Organization. Novel coronavirus disease (COVID-2019) situation reports 97. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200318-sitrep-58-covid-19.pdf?sfvrsn=20876712_2
[10]
Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382(10): 970-1.
[http://dx.doi.org/10.1056/NEJMc2001468] [PMID: 32003551]
[11]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[12]
Cheng ZJ, Shan J. novel coronavirus: where we are and what we know. Infection 2019; 2020: 1-9.
[http://dx.doi.org/10.1007/s15010-020-01401-y] [PMID: 32072569]
[13]
Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382(12): 1177-9.
[http://dx.doi.org/10.1056/NEJMc2001737] [PMID: 32074444]
[14]
Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104(3): 246-51.
[http://dx.doi.org/10.1016/j.jhin.2020.01.022] [PMID: 32035997]
[15]
Guan WJ, Liang WH, Zhao Y, et al. China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55(5): 2000547.
[http://dx.doi.org/10.1183/13993003.00547-2020] [PMID: 32217650]
[16]
World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus [nCoV] infection is suspected. Available from: https://www.who.int/publications-detail/clinical-managementof-
[17]
Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020; 7(1): 4.
[http://dx.doi.org/10.1186/s40779-020-0233-6] [PMID: 32029004]
[18]
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systemic review. J Med Virol 2020; 92(5): 479-90.
[http://dx.doi.org/10.1002/jmv.25707 ] [PMID: 32052466]
[19]
Multicenter collaboration group of department of science and technology of guangdong province and health commission of guangdong province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43(3): 185-8.
[http://dx.doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009] [PMID: 32075365]
[20]
World Health Organization. Off-label use of medicines for COVID-19 Scientific brief 2020. Available from
[http://dx.doi.org/[https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19 ]
[21]
Singhal T. A review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020; 87(4): 281-6.
[http://dx.doi.org/10.1007/s12098-020-03263-6] [PMID: 32166607]
[22]
Chang D, Xu H, Rebaza A, Sharma L, Dela Cruz CS. Protecting health-care workers from subclinical coronavirus infection. Lancet Respir Med 2020; 8(3)e13
[http://dx.doi.org/10.1016/S2213-2600(20)30066-7 ] [PMID: 32061333]
[23]
World Health Organization. Coronavirus disease [COVID-19] technical guidance: infection prevention and control. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/infection-prevention-and-control
[24]
HospiMedica. International staff writers Fujifilm’s antiviral becomes first approved drug to treat coronavirus in China Available from: https://www.hospimedica.com/covid-19/articles/29478-1247/fujifilms-antiviral-becomes-first-approved-drug-to-treatcoronavirus-in-china.html
[25]
Centers for Disease Control and Prevention. Information for clinicians on investigational therapeutics for patients with COVID-19 Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
[26]
The Italian Medicines Agency (AIFA). Drugs usable for the treatment of COVID-19 disease Available from: https://www.aifa.gov.it/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19
[27]
Spanish Agency for Medicines and Health Products (AEMPS). Treatments available for the management of respiratory infection by SARS-CoV-2 Available from: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-delcovid%E2%80%9119/tratamientos-disponibles-para-el-manejode-la-infeccion-respiratoria-por-sars-cov-2/
[28]
French High Council for Public Health. SARS-CoV-2: therapeutic recommendations. Available from: https://www.hcsp.fr/Explore.cgi/AvisRapportsDomaine?clefr=801
[29]
National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: critical care in adults Avaialbale from: https://www.nice.org.uk/guidance/NG159 (Accessed 27 April 2020).
[30]
The Federal Agency for Medicines and Health Products (FAMHP). Coronavirus: state of stocks of hospital drugs Available from: https://www.afmps.be/fr/news/coronavirus_etat_des_stocks_de_medicaments_hospitaliers
[31]
The National Institute for Health and the Environment of the Netherlands. Drug treatment options in patients with COVID-19 (infections with SARS-CoV-2). Available from: https://swab.nl/nl/covid-19

© 2022 Bentham Science Publishers | Privacy Policy